• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia

tetano

Editor, Senior Moderator
Cureus


. 2022 Dec 11;14(12):e32419.
doi: 10.7759/cureus.32419. eCollection 2022 Dec.
Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia


Lujain Alassaf[SUP] 1 [/SUP], Sami Almudarra[SUP] 2 [/SUP], Abdullah Almudaiheem[SUP] 3 [/SUP], Hind Almutlaq[SUP] 4 [/SUP], Ada Alqunaibet[SUP] 3 [/SUP], Haleemah Alseraihi[SUP] 5 [/SUP], Rehab Alaswad[SUP] 3 [/SUP], Abdullah T Khoja[SUP] 6 [/SUP], Khaled AlAbdulkareem[SUP] 7 [/SUP], Faisal AlSaif[SUP] 8 [/SUP], Raghib Abu Saris[SUP] 9 [/SUP]



Affiliations

Abstract

Introduction The new coronavirus disease 2019 (COVID-19) is a major global concern. Due to the number of asymptomatic cases that go untested, the actual proportion of those who have been infected is likely to be higher than the reported prevalence. Thus, investigating the exact proportion of those who developed antibodies against the virus through serological surveys is crucial to identify the immune status of the population and direct public health decisions accordingly. Objectives The aim of this study is to estimate the seroprevalence of SARS-CoV-2 in the community and to describe the epidemiological characteristics of the discovered cases. Methods Between July and October 2020, a cross-sectional sero-survey was conducted including a total of 15,873 serum samples collected from seven regions within the kingdom. Using a multistage convenient sampling, people were invited to participate in an interviewer-administrated questionnaire. Afterward, blood samples were collected and seroprevalence was determined using the SARS-CoV-2 virus IgG/IgM antibody detection kits (ELISA). A p-value of <0.05 and 95% CI were used to report the significance. Results The overall seroprevalence of SARS-CoV-2 in the sample was 17.0%, and Makkah region constituted the highest number of reactive cases (33.3%). There was a significant association between all comorbidities and having symptoms except for diabetes. In addition, age, education, nationality, and region were all significant predeterminants of sero-result. Also, contact with a confirmed or suspected case increased the risk of being seropositive by nearly 1.5 times. Conclusion This study estimated the national seroprevalence of SARS-CoV-2 in Saudi Arabia to be 17%. At the time of this study, most of the population did not have the SARS-CoV-2 specific antibodies. This suggests that the population is still below the threshold of herd immunity and emphasizes the importance of mass vaccination programs and abiding by recommended prevention precautions.

Keywords: covid-19; sars-cov-2; saudi arabia; serological survey; seroprevalence.
 
Back
Top Bottom